Factor Xa Inhibitor [EPC]

Known as: Factor 10a Inhibitor, Activated Factor X Inhibitor, Activated Factor 10 Inhibitor 
 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

Antithrombin III
Factor Xa inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban
The majority of embolisms associated with atrial fibrillation (AF) are from the left atrial appendage (LAA). To treat the… (More)
  • figure 1
  • figure 2
Is this relevant?
2015
2015
Nontraumatic spinal subdural hematoma complicating direct factor Xa inhibitor treatment (rivaroxaban): a challenging management
We report on a 72-year-old male patient who developed a nontraumatic spinal subdural hematoma (SSDH) during rivaroxaban therapy… (More)
  • figure 2
  • figure 1
Is this relevant?
2015
2015
Thrombin generation induced by tissue factor plus ADP in human platelet rich plasma: A potential new measurement to assess the effect of the concomitant use of an oral factor Xa inhibitor edoxaban…
INTRODUCTION Patients with atrial fibrillation undergoing percutaneous coronary intervention may require combination therapy with… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Dual antiplatelet agents and Rivaroxaban for massive intracoronary thrombus in STEMI
Management of intracoronary thrombus in patients presenting more than 12 hours after the onset of ST elevation myocardial… (More)
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial…
OBJECTIVES The aim of this study was to determine the risk of major clinical and thromboembolic events after cardioversion for… (More)
  • table 1
  • table 2
Is this relevant?
2014
2014
Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
Edoxaban, an oral direct factor Xa inhibitor, has proven antithrombotic efficacy. In a multicenter, phase II study, 264 total hip… (More)
  • table 1
  • table 2
Is this relevant?
2014
2014
Intracranial Hemorrhage in Patient Treated with Rivaroxaban
Rivaroxaban is an oral factor Xa inhibitor used for stroke prevention in atrial fibrillation. There are currently no evidence… (More)
  • figure 1
Is this relevant?
2013
2013
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
OBJECTIVES The aim of this study was to determine if rivaroxaban is associated with a reduction in stent thrombosis among… (More)
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2013
2013
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
BACKGROUND Apixaban is an oral, selective, direct factor Xa inhibitor approved for thromboprophylaxis after orthopedic surgery… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2013
2013
Fondaparinux as an alternative to vitamin K antagonists in haemodialysis patients.
BACKGROUND Accelerated vascular calcification and increased risk of calciphylaxis can be a reason to restrict the use of vitamin… (More)
  • table 1
  • table 2
Is this relevant?